Seth Maliske
A5074827009- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Colorectal and Anal Carcinomas
- Kawasaki Disease and Coronary Complications
- Appendicitis Diagnosis and Management
- Acute Lymphoblastic Leukemia research
- Colorectal Cancer Surgical Treatments
- Abdominal Trauma and Injuries
- Sarcoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Trauma and Emergency Care Studies
- Silicon Carbide Semiconductor Technologies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Nephrotoxicity and Medicinal Plants
- Multiple and Secondary Primary Cancers
- Chronic Myeloid Leukemia Treatments
- Vasculitis and related conditions
- Patient-Provider Communication in Healthcare
- Dialysis and Renal Disease Management
- Potassium and Related Disorders
- Health and Medical Studies
University of Iowa
2013-2024
Sanford Health
2023
University of Iowa Hospitals and Clinics
2014-2022
Aspirus Wausau Hospital
2017-2020
Regional Cancer Center
2017-2020
PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There no consensus regarding the optimal approach to prophylaxis. This study was designed determine whether high-dose methotrexate (HD-MTX) effective at preventing in patients high risk this complication. PATIENTS AND METHODS Patients age 18-80 years with lymphoma and progression, treated curative-intent anti–CD20-based chemoimmunotherapy, were included international, retrospective,...
Although checkpoint inhibitors have been approved in multiple cancers, they are still under investigation soft tissue sarcoma (STS). We conducted a retrospective review to report the safety, efficacy, and prognostic factors related STS. A sequential cohort of metastatic STS patients from four institutions treated with was assembled. Logistic Cox regression models were applied determine effect patient characteristics, prior treatment, baseline on achieving best overall response complete (CR),...
Abstract Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) HIV-BL from 2008 to 2019 aiming identify prognostic factors and outcomes. With a median follow up 4.5 years, the 3-year progression-free survival (PFS) overall (OS) were 61% (95% confidence interval [CI] 55% 67%) 66% (95%CI 59% 71%), respectively, similar results both countries....
Abstract Plasmablastic lymphoma (PBL) is a rare entity, commonly associated with immunosuppressed states such as human immunodeficiency virus (HIV) infection or solid organ transplant. The clinical course characterized by high relapse rates and poor prognosis, leading some clinicians to recommend aggressive frontline therapy. However, specific review of limited stage (LS) PBL patients not available evaluate outcomes justify treatment recommendations. We performed retrospective LS cases...
Central nervous system (CNS) involvement in Burkitt lymphoma (BL) poses a major therapeutic challenge, and the relative ability of contemporary regimens to treat CNS remains uncertain. We described prognostic significance incidence recurrence/progression after immunochemotherapy using real-world clinicopathologic data on adults with BL diagnosed between 2009 2018 across 30 US institutions. examined associations baseline involvement, patient characteristics, complete response (CR) rates,...
Chimeric antigen receptor T-cell (CAR-T) therapy is the new standard of care in fit patients with refractory or early relapsed diffuse large B-cell lymphoma (DLBCL). However, there may still be a role for salvage chemotherapy (ST) and autologous stem cell transplant (ASCT) certain circumstances (eg, lack CAR-T resources, chemosensitive relapses, etc). We retrospectively studied 230 DLBCL who underwent ST ASCT. Median line was 1 (range 1-3). Best response before ASCT complete (CR) 106 (46%)...
Abstract Over the last two decades, frontline therapy for mantle cell lymphoma (MCL) has evolved. However, impact of subsequent lines on survival outcomes not been well characterized. In this study, we investigated treatment patterns and in patients with relapsed/refractory (R/R) MCL treated second-line (2 L) therapy. Adult newly diagnosed from 2002 to 2015 were enrolled a prospective cohort study. Clinical characteristics, 2 L details, compared between who received 2003–2009 (Era 1),...
Objective/Background Discussion of treatment goals between oncologists and patients is challenging. Patients frequently misunderstand therapy. There are several methods to document chemotherapy, however, not incorporated into patient charts. Methods/Design Cancer receiving their first cycle chemotherapy were interviewed. Patients’ recall discussions with oncologist regarding therapy intent was assessed compared documentation. An adjusted McNemar's test utilised. A one-sample proportion used...
Neoadjuvant chemoradiotherapy (nCRT) has been shown to achieve decreased local recurrence (LR) with lower toxicity in rectal cancer patients, but data confirming the optimal timing of surgery following this therapy is less robust.The University Iowa Cancer Registry was queried identify all patients stages II-III who received nCRT and from 2000 through 2012. Primary endpoints were time interval (TI), overall survival (OS). Secondary included pathologic outcomes, perioperative morbidities...
Evans syndrome (ES) is a rare disease characterized by simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) with without neutropenia. Splenectomy one the treatment options for refractory to medical therapy. Venous thromboembolism (VTE) following splenectomy hematological diseases has an incidence 10%. Here we describe case report young patient hospitalized severe Hgb 4.8 g/dl. He developed platelet nadir 52,000/mm3, thus formally...
The standard of care (SOC) for fit patients with relapsed diffuse large B-cell lymphoma (DLBCL) ≥12 months after completing frontline therapy is salvage chemotherapy (ST) followed by autologous stem cell transplant (ASCT). However, this strategy may not be optimal certain clinical characteristics. We retrospectively studied 151 DLBCL that R-CHOP or R-CHOP-like who underwent ST and ASCT at Mayo Clinic between July 2000 December 2017 the University Iowa April 2003 2020. Clinical...
7522 Background: Patients with newly diagnoseddiffuse large B-cell lymphoma (DLBCL) who achieve event-free survival at 24 months (EFS24) following immunochemotherapy (IC) have excellent overall (OS) similar to that of age- and sex-matched general population. The standard care for patients relapsed or refractory (RR) DLBCL frontline IC is salvage therapy followed by autologous stem cell transplant (ASCT). goal this study evaluate the role progression-free (PFS) (PFS24) as a landmark after...